NO920671D0 - Fremgangsmaate for aktivering av rekombinante proteiner - Google Patents

Fremgangsmaate for aktivering av rekombinante proteiner

Info

Publication number: NO920671D0
Authority: NO; Norway
Prior art keywords: recombinant proteins; procedure; amino acids; activating recombinant; activating
Prior art date: 1991-02-21

Application number

NO920671A

Other languages

English (en)

Other versions

NO920671L (no

NO300329B1 (no

Inventor

Dorothea Ambrosius

Carola Dony

Rainer Rudolph

Original Assignee

Boehringer Mannheim Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-21

Filing date

1992-02-20

Publication date

1992-02-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6425597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO920671(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-02-20 Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh

1992-02-20 Publication of NO920671D0 publication Critical patent/NO920671D0/no

1992-08-24 Publication of NO920671L publication Critical patent/NO920671L/no

1997-05-12 Publication of NO300329B1 publication Critical patent/NO300329B1/no

Links

238000000034 method Methods 0.000 title abstract 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract 2
230000003213 activating effect Effects 0.000 title abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
238000004153 renaturation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Crystallography & Structural Chemistry (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Dental Preparations (AREA)
Manufacture Of Macromolecular Shaped Articles (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO920671A 1991-02-21 1992-02-20 Fremgangsmåte for aktivering av rekombinante proteiner NO300329B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4105480A DE4105480A1 (de)	1991-02-21	1991-02-21	Verbesserte aktivierung von rekombinanten proteinen

Publications (3)

Publication Number	Publication Date
NO920671D0 true NO920671D0 (no)	1992-02-20
NO920671L NO920671L (no)	1992-08-24
NO300329B1 NO300329B1 (no)	1997-05-12

Family

ID=6425597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO920671A NO300329B1 (no)	1991-02-21	1992-02-20	Fremgangsmåte for aktivering av rekombinante proteiner

Country Status (20)

Country	Link
US (1)	US5578710A (no)
EP (1)	EP0500108B1 (no)
JP (1)	JP2528232B2 (no)
KR (1)	KR950014493B1 (no)
AT (1)	ATE144284T1 (no)
AU (1)	AU641081B2 (no)
CA (1)	CA2061569C (no)
CZ (1)	CZ282744B6 (no)
DE (2)	DE4105480A1 (no)
DK (1)	DK0500108T3 (no)
ES (1)	ES2093122T3 (no)
FI (1)	FI106029B (no)
GR (1)	GR3021395T3 (no)
HU (1)	HU214881B (no)
IE (1)	IE920276A1 (no)
IL (1)	IL101024A (no)
MX (1)	MX9200709A (no)
NO (1)	NO300329B1 (no)
NZ (1)	NZ241570A (no)
ZA (1)	ZA921230B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5718893A (en) *	1984-04-15	1998-02-17	Foster; Preston F.	Use of G-CSF to reduce acute rejection
US5581476A (en)	1993-01-28	1996-12-03	Amgen Inc.	Computer-based methods and articles of manufacture for preparing G-CSF analogs
SE9301057L (sv) *	1993-03-30	1994-10-01	Pharmacia Ab	Beredning med kontrollerad frisättning
US5536495A (en) *	1994-04-15	1996-07-16	Foster; Preston F.	Use of G-CSF to reduce acute rejection
US20030053982A1 (en)	1994-09-26	2003-03-20	Kinstler Olaf B.	N-terminally chemically modified protein compositions and methods
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US6245740B1 (en)	1998-12-23	2001-06-12	Amgen Inc.	Polyol:oil suspensions for the sustained release of proteins
JP4799803B2 (ja)	2000-09-08	2011-10-26	マサチューセッツインスティテュートオブテクノロジー	Ｇ−ｃｓｆアナログ組成物および方法
MXPA03007316A (es)	2001-02-19	2003-12-04	Merck Patent Gmbh	Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
PL371781A1 (en)	2001-07-11	2005-06-27	Maxygen Holdings, Ltd.	G-csf conjugates
US7557195B2 (en)	2002-03-20	2009-07-07	Biopolymed, Inc.	Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
US7666627B2 (en) *	2002-08-08	2010-02-23	Targetex Kft.	Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US7695723B2 (en)	2002-12-31	2010-04-13	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en)	2002-12-31	2010-08-31	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors
US7220407B2 (en)	2003-10-27	2007-05-22	Amgen Inc.	G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060153799A1 (en)	2004-11-05	2006-07-13	Northwestern University	Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP1888119B1 (en)	2005-06-01	2011-03-09	Maxygen, Inc.	Pegylated g-csf polypeptides and methods of producing same
CL2007002166A1 (es) *	2006-07-24	2008-01-25	Tetralogic Pharm Corp	Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
EP2578677A1 (en)	2007-08-09	2013-04-10	Genzyme Corporation	Method of treating autoimmune disease with mesenchymal stem cells
US8758761B2 (en)	2007-09-30	2014-06-24	University Of Florida Research Foundation, Inc.	Combination therapies for treating type 1 diabetes
US8283372B2 (en)	2009-07-02	2012-10-09	Tetralogic Pharmaceuticals Corp.	2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011109556A2 (en)	2010-03-04	2011-09-09	Pfenex Inc.	Method for producing soluble recombinant interferon protein without denaturing
MX2012010661A (es)	2010-03-17	2013-03-25	Biogenerix Gmbh	Metodo para obtener factor estimulante de colonias de granulocitos (g-csf) humano recombinante biologicamente activo.
NZ603033A (en)	2010-04-01	2014-06-27	Pfenex Inc	Methods for g-csf production in a pseudomonas host cell
BR112015002091A2 (pt) *	2012-08-02	2017-12-12	Hoffmann La Roche	método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4532207A (en) *	1982-03-19	1985-07-30	G. D. Searle & Co.	Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
DK55685A (da) *	1985-02-07	1986-08-08	Nordisk Gentofte	Enzym eller enzymkompleks med proteolytisk aktivitet
US4530787A (en) *	1984-03-28	1985-07-23	Cetus Corporation	Controlled oxidation of microbially produced cysteine-containing proteins
US5082775A (en) *	1984-05-11	1992-01-21	Berlex Laboratories, Inc.	Efficient process for isolating insoluble heterologous protein using non-ionic detergents
US4948729A (en) *	1985-03-25	1990-08-14	Cetus Corporation	Production of soluble recombinant proteins
US4783415A (en) *	1985-03-28	1988-11-08	Meiji Seika Kabushiki Kaisha	Gene coding for signal peptides and utilization thereof
US5087564A (en) *	1985-06-20	1992-02-11	Monsanto Company	Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3636903A1 (de) *	1985-12-21	1987-07-02	Hoechst Ag	Fusionsproteine mit eukaryotischem ballastanteil
JPH0618781B2 (ja) *	1986-10-18	1994-03-16	中外製薬株式会社	感染症治療剤
EP0305500B1 (en) *	1987-03-20	1994-11-09	Creative Biomolecules, Inc.	Process for the purification of recombinant polypeptides
US5013653A (en) *	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
WO1988010299A1 (en) *	1987-06-24	1988-12-29	Novo-Nordisk A/S	A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
DE3835350A1 (de) *	1988-10-17	1990-04-19	Boehringer Mannheim Gmbh	Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
ZA901719B (en) *	1989-03-19	1991-01-30	Akzo Nv	Hog cholera virus vaccine and diagnostics
US5191063A (en) *	1989-05-02	1993-03-02	University Of Medicine And Dentistry Of New Jersey	Production of biologically active polypeptides by treatment with an exogenous peptide sequence
US5115102A (en) *	1989-07-21	1992-05-19	Monsanto Company	Variant proteins and polypeptides possessing enhanced affinity for immobilized-metal affinity matrices
AU8417091A (en) *	1990-08-20	1992-03-17	Novo Nordisk A/S	Biologically active compound, a process for the preparation thereof and use of the same

1991
- 1991-02-21 DE DE4105480A patent/DE4105480A1/de not_active Withdrawn
1992
- 1992-01-28 IE IE027692A patent/IE920276A1/en not_active IP Right Cessation
- 1992-02-10 NZ NZ241570A patent/NZ241570A/en not_active IP Right Cessation
- 1992-02-14 AU AU10948/92A patent/AU641081B2/en not_active Ceased
- 1992-02-20 FI FI920742A patent/FI106029B/fi not_active IP Right Cessation
- 1992-02-20 IL IL10102492A patent/IL101024A/en not_active IP Right Cessation
- 1992-02-20 ES ES92102864T patent/ES2093122T3/es not_active Expired - Lifetime
- 1992-02-20 CZ CS92499A patent/CZ282744B6/cs not_active IP Right Cessation
- 1992-02-20 ZA ZA921230A patent/ZA921230B/xx unknown
- 1992-02-20 AT AT92102864T patent/ATE144284T1/de not_active IP Right Cessation
- 1992-02-20 DE DE59207351T patent/DE59207351D1/de not_active Revoked
- 1992-02-20 MX MX9200709A patent/MX9200709A/es not_active IP Right Cessation
- 1992-02-20 DK DK92102864.3T patent/DK0500108T3/da active
- 1992-02-20 EP EP92102864A patent/EP0500108B1/de not_active Revoked
- 1992-02-20 JP JP4033257A patent/JP2528232B2/ja not_active Expired - Lifetime
- 1992-02-20 HU HU9200548A patent/HU214881B/hu not_active IP Right Cessation
- 1992-02-20 CA CA002061569A patent/CA2061569C/en not_active Expired - Fee Related
- 1992-02-20 NO NO920671A patent/NO300329B1/no unknown
- 1992-02-21 KR KR1019920002697A patent/KR950014493B1/ko not_active Expired - Fee Related
1993
- 1993-10-21 US US08/139,054 patent/US5578710A/en not_active Expired - Lifetime
1996
- 1996-10-17 GR GR960402469T patent/GR3021395T3/el unknown

Also Published As

Publication number	Publication date
DE59207351D1 (de)	1996-11-21
IL101024A0 (en)	1992-11-15
NO920671L (no)	1992-08-24
CA2061569C (en)	2000-10-24
NZ241570A (en)	1994-09-27
NO300329B1 (no)	1997-05-12
ES2093122T3 (es)	1996-12-16
DE4105480A1 (de)	1992-08-27
IE920276A1 (en)	1992-08-26
GR3021395T3 (en)	1997-01-31
JP2528232B2 (ja)	1996-08-28
EP0500108B1 (de)	1996-10-16
FI920742L (fi)	1992-08-22
EP0500108A3 (en)	1993-04-07
MX9200709A (es)	1992-09-01
US5578710A (en)	1996-11-26
DK0500108T3 (da)	1997-03-24
HU9200548D0 (en)	1992-04-28
JPH05244977A (ja)	1993-09-24
FI106029B (fi)	2000-11-15
ATE144284T1 (de)	1996-11-15
EP0500108A2 (de)	1992-08-26
HUT68021A (en)	1995-04-04
CA2061569A1 (en)	1992-08-22
CS49992A3 (en)	1992-09-16
FI920742A0 (fi)	1992-02-20
AU1094892A (en)	1992-08-27
AU641081B2 (en)	1993-09-09
IL101024A (en)	1996-06-18
CZ282744B6 (cs)	1997-09-17
KR950014493B1 (ko)	1995-12-02
ZA921230B (en)	1992-11-25
KR920016464A (ko)	1992-09-24
HU214881B (hu)	1998-07-28

Publication	Publication Date	Title
NO920671D0 (no)	1992-02-20	Fremgangsmaate for aktivering av rekombinante proteiner
DE69033040D1 (de)	1999-05-12	Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
DK0535091T3 (da)	1996-05-06	Knogleinducerende farmaceutiske formuleringer
ES2120964T3 (es)	1998-11-16	Peptidos osteogenicos.
DE59101580D1 (de)	1994-06-09	Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.
DE3688324D1 (de)	1993-05-27	Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
ES2124247T3 (es)	1999-02-01	Conjugado de calcitonina y de polietilenglicol.
DE68907635D1 (de)	1993-08-26	Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
ATE255638T1 (de)	2003-12-15	Nukleotidsequenzen und gegen cycloheximid resistente proteine
DK1431391T3 (da)	2005-12-19	RANTES-mutanter og terapeutiske anvendelser heraf
FR2635527B1 (fr)	1992-06-12	Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
SE9602822D0 (sv)	1996-07-19	New receptor
DE68910771D1 (de)	1993-12-23	Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
ES2053620T3 (es)	1994-08-01	Derivados de (2-ciano-2-oximinoacetil)-aminoacidos.
DE59109235D1 (de)	2002-05-29	Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
IT8719551A0 (it)	1987-03-03	Plasmidi ricombinanti utili perl'espressione in bacillus di proteine eterologhe.
DE58909208D1 (de)	1995-06-08	Verfahren zur Herstellung von Imidazol-2-carbonsäuren.
DE59208025D1 (de)	1997-03-20	Neue thrombininhibitorische proteine aus landblutegeln
DE69534738D1 (de)	2006-04-06	Leukocyten-aktivierender Faktor
ATE87906T1 (de)	1993-04-15	(2-cyan-2-oximinoacetyl)-aminosaeure-derivate.
DE58909261D1 (de)	1995-06-29	Ancrod-proteine, ihre herstellung und verwendung.
MX9205978A (es)	1993-04-01	Nuevas proteinas inhibidoras de trombina de garrapatas.
ATE76081T1 (de)	1992-05-15	Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.